ASX / Media Release
7 November 2025

Resignation of Directors, Company Secretary and Cancellation of Requisitioned General Meeting

Invex Therapeutics Ltd (**Invex**, **ASX:IXC,** or **the Company**) refers to the general meeting which is scheduled to be held on 10 November 2025 at Thomson Geer, Level 29 Central Park Tower, 152-158 St Georges Terrace Perth WA 6000 (**Requisitioned Meeting**).

The Requisitioned Meeting was called in response to a requisition notice under s249D of the Corporations Act (**s249D Notice**) received from Celtic Capital Pte Ltd <Investment 1 A/C> (**Requisitioning Shareholder**), to move resolutions at a general meeting of the Company to remove as Directors:

- Chairman, Mr David McAuliffe;
- Executive Director, Dr Thomas Duthy; and
- any person appointed as a Director during the period on and from 15 September 2025 and ending on the commencement of the Requisitioned Meeting.

Mr David McAuliffe and Dr Thomas Duthy have resigned as Directors of the Company, with immediate effect.

Ms Narelle Warren has also resigned as Company Secretary and Chief Financial Officer of the Company, with immediate effect.

As a result of the above-mentioned resignations, the Requisitioning Shareholder has formally withdrawn the s249D Notice, and accordingly, the Requisitioned Meeting has been **cancelled, and will not proceed**. Shareholders are requested not to attend the (now cancelled) Requisitioned Meeting on 10 November 2025.

- ENDS -

This release dated 7 November 2025 has been authorised for lodgement to ASX by Director David Wheeler.

About Invex Therapeutics Ltd

Invex is a biopharmaceutical company focused on the repurposing of an already approved drug, Exenatide, for efficacious treatment of neurological conditions derived from or involving raised intracranial pressure. Invex has trademarked its repurposed Exenatide as Presendin™. www.invextherapeutics.com.